Micafungin

Generic Name: Micafungin

Brand Names: Mycamine

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₇₁N_₉O_₂₃S

CAS Number: 235114-32-6

Unique Ingredient Identifier: R10H71BSWG

Background: Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Indication: Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.

Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Associated Conditions: Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis

Clinical Trials

Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration

Phase 4

Completed

Conditions: Candida Sepsis

Interventions: Drug: Micafungin

First Posted Date: 2016-01-08

Last Posted Date: 2016-01-08

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 10

Registration Number: NCT02651038

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

Phase 4

Terminated

Conditions: Candidiasis
Aspergillosis

Interventions: Drug: Micafungin

First Posted Date: 2016-01-06

Last Posted Date: 2024-11-07

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 105

Registration Number: NCT02646800

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

Phase 4

Terminated

Conditions: Invasive Aspergillosis

Interventions: Drug: Micafungin

First Posted Date: 2016-01-06

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 43

Registration Number: NCT02646774

Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia

Phase 2

Completed

Conditions: Acute Leukemia

Interventions: Drug: Micafungin

First Posted Date: 2015-05-12

Last Posted Date: 2021-11-09

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 66

Registration Number: NCT02440178

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Phase 2

Completed

Conditions: Mycoses
Candidiasis, Invasive
Candidemia

Interventions: Drug: SCY-078
Drug: Fluconazole
Drug: Micafungin

First Posted Date: 2014-09-19

Last Posted Date: 2024-06-25

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 27

Registration Number: NCT02244606

Locations: 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
South Texas Veterans Healthcare System, San Antonio, Texas, United States

and more 27 locations